| Date | Title | Description |
| 22.07.2014 | MoneyTree Reports $121M in MI Venture Deals Last Quarter | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Venture Capital investors had a very active second quarter of 2014, according to the latest MoneyTree report. VCs invested almost $13 billion in 1,114 U.S. startups during the... |
| 22.04.2014 | ProNAi Therapeutics Closes on $59.5M to Advance Cancer Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
ProNAi Therapeutics, a Plymouth, MI-based developer of novel nucleic acid treatments targeting cancer and other genetic diseases, said this week that it has closed a Series D ... |
| 21.04.2014 | ProNAi raises $60 million to advance treatment to combat lymphoma | Among the applications for its PNT2258 treatment are diffuse large B-cell lymphoma, Richter’s transformation, and follicular lymphoma. The funds will also support drug manufacturing, advance development of preclinical drug candidates and th... |
| 18.06.2010 | CytoPherx drums up $11.7 million for dialysis development | By Brandon Glenn
CytoPherx Inc. raised $11.7 million for the development of a device that filters the blood of kidney-disease patients.
The Ann Arbor, Mich.-based company is creating hollow-fiber dialysis filters, which doctors use to isola... |
| 18.06.2010 | CytoPherx raises $5M to develop dialysis filters | The lead investor in the round was Diamond Capital Management of Midland, Michigan, with participation by Apjohn Ventures, a Kalamazoo, Mich.-based venture capital firm, and Chicago-based Lurie Investment Fund.
The fundraise comes in the fo... |
| - | ProNAi raises $60 million to advance treatment to combat lymphoma | Cancer drug developer ProNAi Therapeutics, which developed a nucleic acid-based DNA-interference technology to cause cancer cell death, has added nine new investors in an oversubscribed Series D round.
The latest fundraise will help support... |
| - | CytoPherx raises $5M to develop dialysis filters | CytoPherx Inc. has raised $5 million of an anticipated $7.5 million Series B round to develop a device that filters the blood of kidney disease patients.
The funding will go toward a clinical trial of the Ann Arbor, Mich. company’s hollow-f... |